

June 1, 2010
AnGes MG, Inc.

A Project of GenomIdea Inc., a Subsidiary of AnGes MG, Inc. is Adopted as
an Okinawa Research-and-Development Aid Project for Creation of New Industry
- Development of High-Efficiency DNA Vaccines
Using Needleless Injector against Pandemic Influenza -

AnGes MG, Inc. is pleased to announce that a project called “Development of High-Efficiency DNA Vaccines Using Needleless Injectors against Pandemic Influenza,” for which application was made by GenomIdea Inc., a Subsidiary of AnGes MG (hereinafter, “GenomIdea”) together with Osaka University, AMBiS Corporation, and Daicel Chemical Industries Ltd., was adopted as an Okinawa Research-and-Development Aid Project for Creation of New Industry (Okinawa Industry Promotion Public Corporation) for fiscal year 2010, and that the adoption was announced on May 31.

This project is intended to develop effective novel DNA vaccines against pandemic influenzas that are predicted to break out all over the world in the future.

As compared to seasonal influenza that periodically breaks out every year, the development of vaccines against diseases, such as pandemic influenzas that suddenly break out, requires quicker actions than conventional responses. DNA vaccines are a revolutionary technology which may shorten the manufacturing of influenza vaccines to the level of several weeks, which normally are said to require several months to several years of development time. Expectations are high for the practical use of DNA vaccines against diseases that suddenly break out like pandemic influenzas.

In this project, GenomIdea will play the central role in establishing techniques for the development of vaccines. It will focus on the development of techniques for injecting vaccines into tissues containing many immune cells (joint development with Osaka University), the development of injection devices such as needleless injectors (joint development with Daicel Chemical Industries Ltd.), and the development of manufacturing techniques for practical product applications (joint development with AMBiS Corporation). The overall aim is to develop useful DNA vaccines with efficacy that can be put into practice and that can also promptly deal with actual needs. Additionally, the project aims to demonstrate the capability of injecting both large animals such as swine and small animals, as well as establishing a vaccine technology which can be expected to have a wide range of indications including its use for livestock.

This project will have negligible effect on AnGes MG’s consolidated business results for the current fiscal year and there will be no revision to the forecast.